Exchange Traded Concepts LLC Boosts Stake in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Exchange Traded Concepts LLC raised its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 485.1% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,899 shares of the medical equipment provider's stock after acquiring an additional 6,549 shares during the period. Exchange Traded Concepts LLC's holdings in Lantheus were worth $771,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Janus Henderson Group PLC raised its stake in Lantheus by 72.7% during the 4th quarter. Janus Henderson Group PLC now owns 6,198,689 shares of the medical equipment provider's stock worth $554,583,000 after buying an additional 2,610,118 shares during the period. Farallon Capital Management LLC grew its holdings in shares of Lantheus by 79.9% in the fourth quarter. Farallon Capital Management LLC now owns 5,316,227 shares of the medical equipment provider's stock valued at $475,590,000 after acquiring an additional 2,361,000 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in shares of Lantheus by 40.5% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,509,332 shares of the medical equipment provider's stock valued at $135,025,000 after acquiring an additional 435,445 shares in the last quarter. Dimensional Fund Advisors LP grew its holdings in shares of Lantheus by 2.3% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,347,082 shares of the medical equipment provider's stock valued at $120,510,000 after acquiring an additional 30,891 shares in the last quarter. Finally, Silvercrest Asset Management Group LLC grew its holdings in Lantheus by 39.1% during the fourth quarter. Silvercrest Asset Management Group LLC now owns 973,888 shares of the medical equipment provider's stock valued at $87,124,000 after purchasing an additional 273,838 shares during the period. Institutional investors own 99.06% of the company's stock.

Lantheus Stock Performance

NASDAQ:LNTH traded up $0.20 during trading hours on Friday, reaching $79.19. The company had a trading volume of 1,537,546 shares, compared to its average volume of 1,015,922. The firm has a market cap of $5.48 billion, a price-to-earnings ratio of 22.50 and a beta of 0.11. The company has a current ratio of 5.74, a quick ratio of 5.46 and a debt-to-equity ratio of 0.49. The firm's 50 day moving average price is $86.79 and its 200-day moving average price is $91.02. Lantheus Holdings, Inc. has a 52 week low of $73.11 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). The company had revenue of $372.76 million for the quarter, compared to the consensus estimate of $377.37 million. Lantheus had a net margin of 16.55% and a return on equity of 36.99%. The business's revenue for the quarter was up .8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.69 EPS. On average, analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the topic of several recent research reports. Truist Financial dropped their target price on Lantheus from $127.00 to $117.00 and set a "buy" rating on the stock in a research report on Thursday, May 8th. B. Riley reduced their target price on Lantheus from $127.00 to $122.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Finally, Wall Street Zen raised Lantheus from a "hold" rating to a "buy" rating in a research note on Thursday, May 8th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus price target of $132.67.

Insider Buying and Selling

In other news, Director Mary Anne Heino sold 26,066 shares of the company's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $76.83, for a total transaction of $2,002,650.78. Following the sale, the director now directly owns 318,650 shares in the company, valued at approximately $24,481,879.50. This represents a 7.56% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 1.50% of the stock is currently owned by insiders.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.